RDNT
RadNet, Inc.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$69.27
+0.68%Year over year
Reported trailing growth
- Revenue
- +18.9%
- EBITDA
- +18.9%
- EBIT
- +39.3%
- EPS
- -30.8%
- Free cash flow
- —
- Operating cash flow
- +21.1%
Forward estimates
Based on analyst estimates
- Revenue
- +18.6%
- EBITDA
- +26.1%
- EPS
- +348.2%
Three-year CAGR
- Revenue
- +12.6%
- EBITDA
- -3.0%
- EBIT
- +25.1%
- Net income
- —
- EPS
- —
- Free cash flow
- +39.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026